Company: XAIR
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021561
Chunk: 35

Company: Beyond Air, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Part I, Item 1
Chunk 35
---
 $810  
    $10  
    $-  
    $820 
  
    Stock-based compensation expense 
    $1,174  
    $521  
    $80  
    $1,775 

    Cash used in operations 
    $(3,473) 
    $(273) 
    $(707) 
    $(4,453)
  
    Cash from (used in) from investing 
     (246) 
     486  
     -  
     240 
  
    Cash from financing 
     8,418  
     -  
     500  
     8,918 
  
    Impact of exchange rates 
     11  
     3  
     4  
     18 
  
    Net change for the period 
    $4,710  
    $216  
    $(203) 
    $4,723 

The
following table summarizes financial performance by business segment for the six months ended September 30, 2025:

    (in thousands) 
    Beyond Air  
    Beyond Cancer  
    NeuroNos  
    Total 
  
    Capital expenditures 
    $445  
    $-  
    $-  
    $445 

    Revenues 
    $3,578  
    $-  
    $-  
    $3,578 
  
    Cost of revenues 
     (3,720) 
     -  
     -  
     (3,720)
  
    Research and development 
     (3,930) 
     (908) 
     (698) 
     (5,536)
  
    Selling, general, and administrative 
     (7,062) 
     (1,712) 
     (826) 
     (9,600)
  
    Loss from operations 
     (11,134) 
     (2,620) 
     (1,524) 
     (15,278)
  
    Interest and finance expense 
     (1,187) 
     -  
     -  
     (1,187)
  
    Other non-operating income/(expense) 
     134  
     (12) 
     7  
     129 
  
    Net loss before income taxes 
    $(12,187)